国会山股神再出手，坚定看好AI医疗！

Core Insights - Nancy Pelosi's stock trading performance has yielded an astonishing return of 16,930% over her 30-year congressional career, significantly outperforming the Dow Jones index's 2,300% increase during the same period [1][8]. Company Overview - Tempus AI, founded in 2015, focuses on AI-enabled precision medicine by integrating clinical and molecular data to accelerate diagnostics, therapy selection, and drug development [2][9]. Business Segments - The company's operations are divided into two main segments: - Diagnostics: Provides genomic sequencing and personalized diagnostic recommendations through its own laboratories, with a revenue of approximately $9.55 billion, reflecting a year-over-year growth of about 111%, driven primarily by increased oncology and genetic testing volumes [3][5]. - Data and Applications: Licenses its extensive medical database and AI algorithms to pharmaceutical companies and research institutions, generating around $3.16 billion in revenue, which represents a 31% year-over-year increase, mainly driven by data licensing [3][6]. Financial Performance - Tempus AI reported approximately $12.7 billion in revenue for the previous year, marking an overall year-over-year growth of about 83% [4][11]. Analyst Ratings - TD Cowen reaffirmed a "Hold" rating for Tempus AI in December, setting a target price of $88, with analysts optimistic about the company's long-term prospects in the medical AI sector, particularly regarding its structured, large-scale medical datasets that enhance pharmaceutical research efficiency [7][11].